Literature DB >> 31279792

Pharmacokinetics of K117 and K127, two novel antidote candidates to treat Tabun poisoning.

K Tekes1, G Karvaly2, S Nurulain3, K Kuca4, K Musilek5, E Adeghate6, Y-S Jung7, H Kalász8.   

Abstract

AIMS: K117 and K127 are bis-pyridinium aldoximes but K117 is a bis-pyridinium bis-aldoxime while K127 has only one single aldoxime in addition to its amide substituent. Is there any difference in pharmacokinetics in these compounds that otherwise have the same chemical structure? Both K117 and K127 are developed as antidotes in acetylcholinesterase and butyrylcholinesterase poisoning in terrorist attacks or intoxication with other organophosphorous compounds. Their distributions have been scouted in the bodies of rats. MAIN
METHODS: White male Wistar rats were intramuscularly injected. The animals were sacrificed, tissue samples were homogenized, and either K117 or K127 concentrations were determined using reversed-phase high-performance liquid chromatography. KEY
FINDINGS: Both K117 and K127 were present in all tissues that were analyzed including blood (serum), the brains, cerebrospinal fluid, the eyes, livers, kidneys, lungs and testes. Their pharmacokinetics and body distributions are similar. SIGNIFICANCE: Either K117 or K127 meets the essential requirements for antidotes. Dose dependence and kinetics of their distribution were compared to that of other pyridinium aldoximes.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Butyrylcholinesterase; Distribution; HPLC; K117; K127; Pyridinium aldoxime

Mesh:

Substances:

Year:  2019        PMID: 31279792     DOI: 10.1016/j.cbi.2019.108737

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  1 in total

1.  Pharmacokinetics of Two Chlorine-Substituted Bis-Pyridinium Mono-Aldoximes with Regenerating Effect on Butyrylcholinesterase.

Authors:  Huba Kalász; Zoltán Szimrók; Gellért Karvaly; Jennifer Adeghate; Kornélia Tekes
Journal:  Molecules       Date:  2020-03-10       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.